EUCTR2020-004997-23-FR进行中（未招募）1 期
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 575
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age >=50-85 years at time of signing the Informed Consent Form
- •Diagnosis of idiopathic Parkinson's disease (PD) based on Movement disorder society (MDS) criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism
- •On symptomatic PD medication for at least 6 months, with stable doses for 3 months prior to baseline
- •A diagnosis of PD for at least 6 months to maximum 3 years at screening
- •Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV score= 0
- •Hoehn and Yahr (H&Y) Stage I or II in ON and OFF states
- •Dopamine transporter imaging with single photon emission computed tomography (DaT-SPECT) imaging consistent with dopamine transporter deficit, as assessed by the central reader
- •No anticipated changes in PD medication from baseline throughout the study duration based on clinical status during screening
- •Willingness and ability to use a smartphone application to measure PD-related symptoms for the duration of the study
- •Willingness and ability to wear a smartwatch to measure PD-related motor signs
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 259
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 316
排除标准
- •Medical history indicating a Parkinsonian syndrome other than idiopathic PD
- •Diagnosis of PD dementia
- •Diagnosis of a significant central nervous system (CNS) disease other than Parkinson’s disease
- •Within the last year, unstable or clinically significant cardiovascular disease
- •Uncontrolled hypertension
- •Drug and/or alcohol abuse within 12 months prior to screening, in the investigator's judgment (Nicotine is allowed, Marijuana use is not allowed)
- •Clinically significant abnormalities in laboratory test results at the screening visit, including hepatic and renal panels, complete blood count, chemistry panel and urinalysis
- •Allergy to any of the components of prasinezumab, a known hypersensitivity, or a previous IRR following administration of any other monoclonal antibody
- •Any contraindications to obtaining a brain MRI
- •Any contraindications to DaT-SPECT imaging
研究者
相似试验
进行中（未招募）
不适用
Treatment of Adult Allergic Asthma Patients with MEMP1972AAllergic AsthmaEUCTR2011-003997-10-HUGENENTECH, Inc.560
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Uncontrolled Severe Asthmancontrolled Severe AsthmaMedDRA version: 19.0 Level: LLT Classification code 10003560 Term: Asthma NOS System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10015888 Term: Extrinsic asthma System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10003561 Term: Asthma, unspecified System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10001705 Term: Allergic asthma System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10003554 Term: Asthma aggravated System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10068393 Term: Neutrophilic asthma System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10022847 Term: Intrinsic asthma System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10074614 Term: Nocturnal asthma System Organ Class: 100000004855MedDRA version: 19.0 Level: LLT Classification code 10003638 Term: Atopic asthma System Organ Class: 100000004855MedDRA version: 19.0EUCTR2016-001549-13-BEGenentech, Inc.501
进行中（未招募）
不适用
Treatment of Adult Allergic Asthma Patients with MEMP1972AMedDRA version: 17.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAllergic AsthmaEUCTR2011-003997-10-BGGENENTECH, Inc.560
未知
不适用
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND DOSING REGIMENS OF MEMP 1972A IN ADULTS WITH ALLERGIC ASTHMA WHO ARE INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROIDS AND A SECOND CONTROLLER (COSTA)PER-079-12GENENTECH, INC.,55
招募中
不适用
A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO ASSESS THE EFFICACY AND SAFETY OF MSTT1041A IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA-J45Nonallergic asthmaJ45J451PER-048-16A24